Status:
COMPLETED
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Shingles
Eligibility:
All Genders
60+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the immunity (the body's protection) against shingles after receiving two doses of an investigational vaccine or placebo (a look alike vaccine with no active ...
Detailed Description
The duration of treatment is 12 weeks.
Eligibility Criteria
Inclusion
- Individuals who are at least 60 years of age with a history of varicella (shingles)
- Females must have been postmenopausal.
Exclusion
- Subjects who did not previously participate in the main study of this protocol.
- Subject had shingles since their 6 month follow-up visit in main phase of study.
Key Trial Info
Start Date :
November 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00109122
Start Date
November 1 2001
End Date
July 1 2006
Last Update
March 15 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.